Siminerio Linda M
Department of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Diabetes Educ. 2008 Jan-Feb;34 Suppl 1:18S-24S. doi: 10.1177/0145721707313938.
Diabetes has reached epidemic proportions, and studies have shown that many patients do not reach optimal glycemic control. Evidence suggests that often there is a long lapse between treatment failure and therapy advancement. A better understanding of the pharmacotherapeutic treatment options, realistic goal-setting, and continued follow-up to support treatment adherence are crucial to improving diabetes care and outcomes. Many possible barriers prevent patients from achieving the desired level of glycemic control, eg, side effects of medications, psychosocial issues, and access to support services. Strategies to overcome these barriers will be presented. Pramlintide, an adjunct to insulin therapy, is the first antihyperglycemic agent to be approved for both type 1 and type 2 diabetes since insulin was developed. Educating patients about the dosing, administration, and side effects of pramlintide before adding it to insulin therapy may improve patient adherence and ultimately optimize treatment outcomes and success.
糖尿病已呈流行态势，研究表明许多患者并未实现最佳血糖控制。有证据表明，治疗失败与治疗进展之间往往存在较长时间的间隔。更好地理解药物治疗选择、设定切实可行的目标以及持续随访以支持治疗依从性对于改善糖尿病护理和治疗效果至关重要。许多可能的障碍会阻碍患者实现理想的血糖控制水平, 例如药物副作用、心理社会问题以及获得支持服务的机会。将介绍克服这些障碍的策略。普兰林肽作为胰岛素治疗的辅助药物，是自胰岛素研发以来首个被批准用于1型和2型糖尿病的抗高血糖药物。在将普兰林肽添加到胰岛素治疗之前，对患者进行关于其剂量、给药方法和副作用的教育，可能会提高患者的依从性，并最终优化治疗效果和成功率。
